Optimal control by ondansetron of acute and delayed emesis induced by non cisplatin containing chemotherapy;CONTROLE OPTIMAL PAR L'ONDANSETRON DES NAUSEES ET VOMISSEMENTS AIGUS ET PROLONGES DANS LES CHIMIOTHERAPIES NE COMPORTANT PAS DE CISPLATINE

Bulletin du Cancer

Volumn 83, Issue 1, 1996, Pages 71-76

  Harousseau, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

chemotherapy induced emesis; cyclophosphamide; ondansetron

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; ANTIEMETIC AGENT;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; META ANALYSIS; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; MALE; NAUSEA; REVIEW; TIME; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NAUSEA; ONDANSETRON; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 0029705336     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118: 407-13
2. Beck TM. The pattern of emesis following high-dose cyclophosphamide and the antiemetic efficacy of ondansetron. Anti Cancer Drugs 1995;6:237-42
3. Bonneterre J, Chevallier B, Metz R et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8:1063-9
4. Buser KS, Joss RA, Piquet D et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-FU (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol 1993;4:475-9
5. Campora E, Giudici S, Merlini L, Rosso R. Control of acute, delayed FEC/FAC-induced emesis and gastrointestinal toxicity at subsequent cycles: a randomized trial of metoclopramide, dexamethasone and orphenadrine versus ondansetron and dexamethasone [abstract 1358]. Proceedings of the 28th Annual Meeting of the American Society of Clinical Oncology, San Diego, 17-19 may 1992;11:390
6. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol 1994;17:137-46
7. Dicato MA, Kaasa S, Campora E et al. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind mullicentre study. Clin Oncol 1992;4:275-9
8. Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Reports 1982;66:1487-93
9. Gisselbrecht C, Harousseau JL, Paillarse JM et le Groupe hématologique français d'étude de l'ondansétron. Prévention des nausées et vomissements induits par les chimiothérapies des lymphomes : comparaison de l'ondansétron et de l'alizapride. Sem Hôp (Paris) 1992;68:758-65
10. Kaasa S, Kvaloy S, Dicato MA et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990;26:311-4
11. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:1050-7
12. Levitt M, Warr D, Yelle L et al, Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993;328:1081-4
13. Lévy E, Paillarse JM, Votan B. Efficacité de l'ondansétron dans les nausées et vomissements radio-induits : revue de la littérature. Bull Cancer Radiother 1994;81:179-85
14. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7:1142-9
15. Marschner NW, Adler M, Nagel GA et al. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991;27: 1137-40
16. Martin M. Myths and realities of antiemetic treatment. Br J Cancer 1992;66 (Suppl XIX):S46-S51
17. Marty M. Actualités de l'ondansétron en pratique clinique. Cah Oncol 1993;2:201-6
18. Marty M. Contrôle des nausées et vomissements chimio-induits en 1994 : approche globale de la stratégie thérapeutique et apports de l'ondansétron. Cah Oncol 1994;3:288-92
19. Richard A, Marty M. Étude des facteurs pronostiques des vomissements induits par les chimiothérapies anticancéreuses chez 2 041 patients. Cah Oncol 1993;2:175-80
20. Roberts JT, Priestman TJ. A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 1993; 50:173-9
21. Roila F, Tonato M, Cognetti F et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8
22. Roila F, Tonato M, Del Favero A. Prognostic factors of chemotherapy-induced emesis. In: Diaz Rubio E, Martin M, eds. Antiemetic therapy: current status and future prospects. Creaciones Elba SA 1992:92-104
23. Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. Eur J Cancer Clin Oncol 1989;25 (Suppl 1):S35-S39
24. Smyth JF, Coleman RE, Nicolson M et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 1991;303:1423-6
25. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992;49:295-304
26. Soukop M, McQuade B, Richard A. Valeur pronostique du contrôle de l'émésis induit par la première cure de cyclophosphamide : étude de l'ondansétron sur six cures. Cah Oncol 1994;3: 284-7
27. Wilcox PM, Petting JH, Nettesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Reports 1982;66:1601-4